Skip to main content
SpringerLink
Log in

Gut Microbiota and HCC

  • Chapter
  • First Online:
Hepatocellular Carcinoma

Part of the book series: Current Clinical Oncology ((CCO))

Abstract

It is well known that chronic hepatic inflammation results in liver fibrosis or cirrhosis and may subsequently lead to the development of hepatocellular carcinoma (HCC). Thus, HCC can be considered as the end stage of most chronic inflammatory liver diseases. There is a growing body of evidence indicating a crucial role of gut microbiota, long appreciated to be a main factor of intestinal inflammation, in this process of hepatic inflammation. Recent studies have elucidated the critical influence of intestinal microbiota-driven proinflammatory stimuli to the hepatic microenvironment and have consequently yielded a central hypothesis whereby the intestinal microflora is of great importance in the pathogenesis of hepatocellular carcinoma. This book chapter summarizes the available literature on this hypothesis and outlines possible therapeutic approaches and future directions in the field of gut microbiota and HCC development.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lederberg J. ‘Ome Sweet’ Omics—A genealogical treasury of words. Sci. 2001;15:8.

    Google Scholar 

  2. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nat. 2010;464:59–65.

    Article  CAS  Google Scholar 

  3. Sekirov I, Russell SL, Antunes LCM, Finlay BB. Gut microbiota in health and disease. Physiol Rev. 2010;90:859–904.

    Article  CAS  PubMed  Google Scholar 

  4. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA. Diversity of the human intestinal microbial flora. Sci. 2005;308:1635–8.

    Article  Google Scholar 

  5. O’Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep. 2006;7:688–93.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Chen TS, Chen PS. Intestinal autointoxication: a medical leitmotif. J Clin Gastroenterol. 1989;11:434–41.

    Article  CAS  PubMed  Google Scholar 

  7. Metchnikoff E, Williams H. Why not live forever? Cosmopolitan. 1912;53:436–46.

    Google Scholar 

  8. Lane WA. The Consequences and Treatment of Alimentary Toxæmia from a Surgical Point of View. Proc R Soc Med. 1913;6:49–117.

    PubMed Central  Google Scholar 

  9. Phillips GB, Schwartz R, Gabuzda GJ, Davidson CS. The syndrome of impending hepatic coma in patients with cirrhosis of the liver given certain nitrogenous substances. N Engl J Med. 1952;247:239–46.

    Article  CAS  PubMed  Google Scholar 

  10. Martini GA, Phear EA, Ruebner B, Sherlock S. The bacterial content of the small intestine in normal and cirrhotic subjects: relation to methionine toxicity. Clin Sci (Lond). 1957;16:35–51.

    CAS  Google Scholar 

  11. Phear EA, Ruebner B, Sherlocks S, Summerskill WH. Methionine toxicity in liver disease and its prevention by chlortetracycline. Clin Sci (Lond). 1956;15:93–117.

    CAS  Google Scholar 

  12. Cirera I, Bauer TM, Navasa M, et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol. 2001;34:32–7.

    Article  CAS  PubMed  Google Scholar 

  13. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371:838–51.

    Article  CAS  PubMed  Google Scholar 

  14. Yeh D-C, Wu C-C, Ho W-M, Cheng S-B, Lu I-Y, Liu T-J, P’eng F-K. Bacterial translocation after cirrhotic liver resection: a clinical investigation of 181 patients. J Surg Res. 2003;111:209–14.

    Article  PubMed  Google Scholar 

  15. Wang X, Pärsson H, Soltesz V, Johansson K, Andersson R. Bacterial translocation and intestinal capillary permeability following major liver resection in the rat. J Surg Res. 1995;58:351–8.

    Article  CAS  PubMed  Google Scholar 

  16. Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, Schwabe RF. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med. 2007;13:1324–32.

    Article  CAS  PubMed  Google Scholar 

  17. Gómez-Hurtado I, Santacruz A, Peiró G, Zapater P, Gutiérrez A, Pérez-Mateo M, Sanz Y, Francés R. Gut microbiota dysbiosis is associated with inflammation and bacterial translocation in mice with CCl4-induced fibrosis. PLoS ONE. 2011;6:e23037.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Galati JS, Holdeman KP, Dalrymple GV, Harrison KA, Quigley EM. Delayed gastric emptying of both the liquid and solid components of a meal in chronic liver disease. Am J Gastroenterol. 1994;89:708–11.

    CAS  PubMed  Google Scholar 

  19. Sadik R, Abrahamsson H, Björnsson E, Gunnarsdottir A, Stotzer PO. Etiology of portal hypertension may influence gastrointestinal transit. Scand J Gastroenterol. 2003;38:1039–44.

    Article  CAS  PubMed  Google Scholar 

  20. Kalaitzakis E, Sadik R, Holst JJ, Ohman L, Björnsson E. Gut transit is associated with gastrointestinal symptoms and gut hormone profile in patients with cirrhosis. Clin Gastroenterol Hepatol. 2009;7:346–52.

    Article  CAS  PubMed  Google Scholar 

  21. Gupta A, Dhiman RK, Kumari S, Rana S, Agarwal R, Duseja A, Chawla Y. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol. 2010;53:849–55.

    Article  PubMed  Google Scholar 

  22. Quigley EM. Gastrointestinal dysfunction in liver disease and portal hypertension. Gut-liver interactions revisited. Dig Dis Sci. 1996;41:557–61.

    CAS  PubMed  Google Scholar 

  23. Stewart JJ, Battarbee HD, Farrar GE, Betzing KW. Intestinal myoelectrical activity and transit time in chronic portal hypertension. Am J Physiol. 1992;263:G474–9.

    CAS  PubMed  Google Scholar 

  24. Dukowicz AC, Lacy BE, Levine GM. Small intestinal bacterial overgrowth: a comprehensive review. Gastroenterol Hepatol (N Y). 2007;3:112–22.

    Google Scholar 

  25. Yang CY, Chang CS, Chen GH. Small-intestinal bacterial overgrowth in patients with liver cirrhosis, diagnosed with glucose H2 or CH4 breath tests. Scand J Gastroenterol. 1998;33:867–71.

    Article  CAS  PubMed  Google Scholar 

  26. Corazza GR, Menozzi MG, Strocchi A, Rasciti L, Vaira D, Lecchini R, Avanzini P, Chezzi C, Gasbarrini G. The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing. Gastroenterol. 1990;98:302–9.

    Article  CAS  Google Scholar 

  27. Mazo IB, Honczarenko M, Leung H, et al. Bone marrow is a major reservoir and site of recruitment for central memory CD8 + T cells. Immunity. 2005;22:259–70.

    Article  CAS  PubMed  Google Scholar 

  28. Chen Y, Yang F, Lu H, Wang B, Chen Y, Lei D, Wang Y, Zhu B, Li L. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatol. 2011;54:562–72.

    Article  Google Scholar 

  29. Teltschik Z, Wiest R, Beisner J, Nuding S, Hofmann C, Schoelmerich J, Bevins CL, Stange EF, Wehkamp J. Intestinal bacterial translocation in rats with cirrhosis is related to compromised Paneth cell antimicrobial host defense. Hepatol. 2012;55:1154–63.

    Article  Google Scholar 

  30. Szabo G, Bala S, Petrasek J, Gattu A. Gut-liver axis and sensing microbes. Dig Dis. 2010;28:737–44.

    Article  PubMed  Google Scholar 

  31. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterol. 2007;132:2557–76.

    Article  CAS  Google Scholar 

  32. McKillop IH, Moran DM, Jin X, Koniaris LG. Molecular pathogenesis of hepatocellular carcinoma. J Surg Res. 2006;136:125–35.

    Article  CAS  PubMed  Google Scholar 

  33. Röcken C, Carl-McGrath S. Pathology and pathogenesis of hepatocellular carcinoma. Dig Dis. 2001;19:269–78.

    Article  PubMed  Google Scholar 

  34. Yu L-X, Yan H-X, Liu Q, et al. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatol. 2010;52:1322–33.

    Article  CAS  Google Scholar 

  35. Maeda S, Kamata H, Luo J-L, Leffert H, Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell. 2005;121:977–90.

    Article  CAS  PubMed  Google Scholar 

  36. Dapito DH, Mencin A, Gwak G-Y, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell. 2012;21:504–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Levental KR, Yu H, Kass L, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009;139:891–906.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Samuel MS, Lopez JI, McGhee EJ, et al. Actomyosin-mediated cellular tension drives increased tissue stiffness and β-catenin activation to induce epidermal hyperplasia and tumor growth. Cancer Cell. 2011;19:776–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Mencin A, Kluwe J, Schwabe RF. Toll-like receptors as targets in chronic liver diseases. Gut. 2009;58:704–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Schwabe RF, Seki E, Brenner DA. Toll-like receptor signaling in the liver. Gastroenterology. 2006;130:1886–900.

    Article  CAS  PubMed  Google Scholar 

  41. Su GL. Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation. Am J Physiol Gastrointest Liver Physiol. 2002;283:G256–65.

    Article  CAS  PubMed  Google Scholar 

  42. Paik Y-H, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology. 2003;37:1043–55.

    Article  CAS  PubMed  Google Scholar 

  43. Sung CYJ, Lee NP-Y, El-Nezami H. Regulation of T helper 17 by bacteria: an approach for the treatment of hepatocellular carcinoma. Int J Hepatol. 2012;2012:439024.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Zhang J-P, Yan J, Xu J, Pang X-H, Chen M-S, Li L, Wu C, Li S-P, Zheng L. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol. 2009;50:980–9.

    Article  CAS  PubMed  Google Scholar 

  45. Kuang D-M, Peng C, Zhao Q, Wu Y, Chen M-S, Zheng L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology. 2010;51:154–64.

    Article  CAS  PubMed  Google Scholar 

  46. Wang W, Wang Z, Liu Y, Qin Y, Shen Q. Increased level of Th17 cells in peripheral blood correlates with the development of hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi. 2010;32:757–61.

    PubMed  Google Scholar 

  47. Zhao F, Hoechst B, Gamrekelashvili J, et al. Human CCR4 + CCR6 + Th17 cells suppress autologous CD8 + T cell responses. J Immunol. 2012;188:6055–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Fox JG, Feng Y, Theve EJ, et al. Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens. Gut. 2010;59:88–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Rogers AB. Distance burning: how gut microbes promote extraintestinal cancers. Gut Microbes. 2011; 2:52–7.

    Google Scholar 

  50. Huang Y, Fan X-G, Wang Z-M, Zhou J-H, Tian X-F, Li N. Identification of helicobacter species in human liver samples from patients with primary hepatocellular carcinoma. J Clin Pathol. 2004;57:1273–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Yang J, Ji S, Zhang Y, Wang J. Helicobacter hepaticus infection in primary hepatocellular carcinoma tissue. Singapore Med J. 2013;54:451–7.

    Article  PubMed  Google Scholar 

  52. Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer. 2011;11:886–95.

    Article  CAS  PubMed  Google Scholar 

  53. Sun B, Karin M. Obesity, inflammation, and liver cancer. J Hepatol. 2012;56:704–13.

    Article  CAS  PubMed  Google Scholar 

  54. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579–91.

    Article  CAS  Google Scholar 

  55. Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci USA. 2005;102:11070–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Bäckhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. Science. 2005;307:1915–20.

    Article  PubMed  Google Scholar 

  57. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444:1022–3.

    Article  CAS  PubMed  Google Scholar 

  58. Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 2013;499:97–101.

    Article  CAS  PubMed  Google Scholar 

  59. Ridlon JM, Kang D-J, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res. 2006;47:241–59.

    Article  CAS  PubMed  Google Scholar 

  60. Hara E. Relationship between Obesity, Gut Microbiome and Hepatocellular Carcinoma Development. Dig Dis. 2015;33:346–50.

    Article  PubMed  Google Scholar 

  61. Coppé J-P, Patil CK, Rodier F, Sun Y, Muñoz DP, Goldstein J, Nelson PS, Desprez P-Y, Campisi J. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008;6:2853–68.

    Article  PubMed  Google Scholar 

  62. Coppé J-P, Desprez P-Y, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5:99–118.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Hawkins LD, Christ WJ, Rossignol DP. Inhibition of endotoxin response by synthetic TLR4 antagonists. Curr Top Med Chem. 2004;4:1147–71.

    Article  CAS  PubMed  Google Scholar 

  64. Mullarkey M, Rose JR, Bristol J, et al. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther. 2003;304:1093–102.

    Article  CAS  PubMed  Google Scholar 

  65. Barochia A, Solomon S, Cui X, Natanson C, Eichacker PQ. Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies. Expert Opin Drug Metab Toxicol. 2011;7:479–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Solomon SB, Cui X, Gerstenberger E, Danner RL, Fitz Y, Banks SM, Natanson C, Eichacker PQ. Effective dosing of lipid A analogue E5564 in rats depends on the timing of treatment and the route of Escherichia coli infection. J Infect Dis. 2006;193:634–44.

    Article  CAS  PubMed  Google Scholar 

  67. Sha T, Sunamoto M, Kitazaki T, Sato J, Ii M, Iizawa Y. Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model. Eur J Pharmacol. 2007;571:231–9.

    Article  CAS  PubMed  Google Scholar 

  68. Kim GP, Mahoney MR, Szydlo D, et al. An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. Invest New Drugs. 2012;30:387–94.

    Article  CAS  PubMed  Google Scholar 

  69. Hernández IG, Delgadillo AT, Vorackova FV, Uribe M. Intestinal flora, probiotics, and cirrhosis. Ann Hepatol 2008; 7:120–4.

    Google Scholar 

  70. Zhang H-L, Yu L-X, Yang W, et al. Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats. J Hepatol. 2012;57:803–12.

    Article  PubMed  Google Scholar 

  71. Nanji AA, Khettry U, Sadrzadeh SM. Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver (disease). Proc Soc Exp Biol Med. 1994;205:243–7.

    Article  CAS  PubMed  Google Scholar 

  72. Wagnerberger S, Spruss A, Kanuri G, Stahl C, Schröder M, Vetter W, Bischoff SC, Bergheim I. Lactobacillus casei Shirota protects from fructose-induced liver steatosis: a mouse model. J Nutr Biochem. 2013;24:531–8.

    Article  CAS  PubMed  Google Scholar 

  73. Cano PG, Santacruz A, Trejo FM, Sanz Y. Bifidobacterium CECT 7765 improves metabolic and immunological alterations associated with obesity in high-fat diet-fed mice. Obesity (Silver Spring). 2013;21:2310–21.

    Article  CAS  Google Scholar 

  74. Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143(913–6):e7.

    PubMed  Google Scholar 

  75. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol. 2012;56:1384–91.

    Article  PubMed  Google Scholar 

  76. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071–81.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany

    Sven H. Loosen & Christoph Roderburg

  2. Department of Medicine III, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074, Aachen, Germany

    Tom Luedde

Authors
  1. Sven H. Loosen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christoph Roderburg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tom Luedde
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sven H. Loosen .

Editor information

Editors and Affiliations

  1. Dokuz Eylul University, Izmir Biomedicine and Genome Center Dokuz Eylul University, Izmir, Izmir, Turkey

    Brian I. Carr

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Loosen, S.H., Roderburg, C., Luedde, T. (2016). Gut Microbiota and HCC. In: Carr, B. (eds) Hepatocellular Carcinoma. Current Clinical Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-34214-6_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-34214-6_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-34212-2

  • Online ISBN: 978-3-319-34214-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation